PATENT CLAIM ANALYSIS

Application Number: 15762031
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "267000"]

Abstract:
The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzheimer's disease and other disorders and diseases in which muscarinic M1 receptors are involved. The invention is further directed to pharmaceutical compositions comprising the novel crystalline forms of Compound I.

Claim (Index 24):
The compound of  claim 23  characterized by an x-ray powder diffraction pattern, collected using copper K-alpha radiation, corresponding to d-spacings of 12.81, 4.52, 4.38, 3.55 and 3.37 angstroms.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.65909
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15305246', '11988780', '11921824', '11633152', '11069724']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7824029937543656
- 35 USC 102 Novelty (BERT): 0.48523975696835
- Combined Prediction Score: 0.7526866700757641
- Mean Citation Score: 228.442428
- Max Citation Score: 237.03865
- Similarity Product: 201.25162940968272

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test